Search Results
125 items found for "design pharmaceuticals"
- 📰 GPCR Weekly News, May 1 to 7, 2023
Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues
- 📰 GPCR Weekly News, March 4 to 10, 2024
all symptoms of schizophrenia Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
- 📰 GPCR Weekly News, June 5 to 11, 2023
GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Industry News X4 Pharmaceuticals
- 📰 GPCR Weekly News, August 14 to 20, 2023
immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business Update Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, September 11 to 17, 2023
Research Associate NEW Research Technician Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, September 4 to 10, 2023
| Chemotactic Cytokines GPCR Jobs NEW Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, May 8 to 14, 2023
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage X4 Pharmaceuticals
- 📰 GPCR Weekly News, April 22 to 28, 2024
great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, April 15 to 21, 2024
great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, February 13 to 19, 2023
GPCR Jobs Computational drug design PhD student at the Department of Drug Design and Pharmacology Computational drug design postdoc at the Department of Drug Design and Pharmacology Software / database development PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at the Department of Drug Design and Pharmacology Postdoc in Bioinformatics/Data Science at Department of Drug Design and Pharmacology Scientist/Senior Scientist (Research Software Engineer) Senior Scientist
- Exscientia is 10 years old this July!
Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design of We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates We’re excited about delivering the next ten years of Exscientia and advancing AI to design better drugs
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
October 2022 "Pepducins are small-lipidated peptides designed from the intracellular loops of G protein-coupled To date, pepducins designed from numerous GPCRs have been studied for their impact on pathologic conditions This review will focus in particular on pepducins designed from protease-activated receptors, C-X-C motif
- 📰 GPCR Weekly News, January 30 to February 5, 2023
GPCR Jobs Computational drug design PhD student at the Department of Drug Design and Pharmacology Computational drug design postdoc at the Department of Drug Design and Pharmacology Software / database development PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at the Department of Drug Design and Pharmacology Postdoc in Bioinformatics/Data Science at Department of Drug Design and Pharmacology Scientist/Senior Scientist (Research Software Engineer) Senior Scientist
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
discovery has the potential to accelerate the identification and development of novel drugs, optimize drug design compared; and 3) detection, prediction, or generation (e.g. prediction of a protein structure, or ligand design De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding Multi-target drug design: GPCRs are often involved in complex signaling networks. With the revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively
- Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures
crystallography and cryo-EM have resulted in a wealth of GPCR structures that have been used in drug design
- Chemogenetic stimulation of the G i pathway in astrocytes suppresses neuroinflammation
Engineered G protein-coupled receptors (GPCRs) are commonly used in chemogenetics as designer receptors exclusively activated by designer drugs (DREADDs).
- Function and structure of bradykinin receptor 2 for drug discovery
molecular insights into the functions and regulation of B2R, which shed light on structure-based drug design
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
Some innovative solutions have been the development of the BERKY and the ONE-GO biosensors, designed The ONE-GO biosensors, designed in a single vector, incorporate a G protein tagged with a YFP acceptor M., et al., Revealing the Activity of Trimeric G-proteins in Live Cells with a Versatile Biosensor Design
- Molecular insights into psychedelic drug action
With the United States Food and Drug Administration's designation of psilocybin as a "Breakthrough Therapy
- Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling
do not reveal a clear conformational basis for signaling bias, which would have enabled the rational design
- Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
side effects, and tools to explore the ORs nature and function, various (poly)pharmacological ligand design
- Structural insights into adhesion GPCR ADGRL3 activation and Gq, Gs, Gi, and G12 coupling
A detailed analysis of the engagements allows us to design mutations that specifically enhance one pathway
- Community guidelines for GPCR ligand bias: IUPHAR review 32
Here, we provide guidelines and terminology for any scientists to design and report ligand bias experiments
- G protein coupling and activation of the metabotropic GABAB heterodimer
provides fresh insights into the mechanistic details of class C GPCRs activation expected to be useful for designing
- Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1
findings fill a gap in the understanding of CB1 allosteric regulation and could guide the rational design
- Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of ligand...
understand the basis of the ligand preferences of the receptors and to assist structure-based drug design
- Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
the identification of allosteric sites as well as ligand-based and structure-based drug discovery and design
- Fusion protein strategies for cryo-EM study of G protein-coupled receptors
Here, we address this shortcoming by exploring different fusion protein designs, which lead to structures